needed to assess whether sensitivity may also improve, as has been shown for patients with type 2 diabetes (44).
In contrast to other antidiabetic drugs, DPP-4 inhibitors display a low risk for hypoglycemia (49). In line with the findings of previous studies in type 2 diabetics, we did not observe any episode of hypoglycemia in NODAT patients treated with vildagliptin after kidney transplantation. Interestingly, preclinical data demonstrate a beneficial effect of gliptins on blood vessels and the heart (50), although a benefit for the cardiovascular system as a whole has still to be proven (27). Unfortunately, such endpoints are also beyond the scope of the present trial. The same is of course true for statistically meaningful determination o
needed to assess whether sensitivity may also improve, as has been shown for patients with type 2 diabetes (44).In contrast to other antidiabetic drugs, DPP-4 inhibitors display a low risk for hypoglycemia (49). In line with the findings of previous studies in type 2 diabetics, we did not observe any episode of hypoglycemia in NODAT patients treated with vildagliptin after kidney transplantation. Interestingly, preclinical data demonstrate a beneficial effect of gliptins on blood vessels and the heart (50), although a benefit for the cardiovascular system as a whole has still to be proven (27). Unfortunately, such endpoints are also beyond the scope of the present trial. The same is of course true for statistically meaningful determination o
การแปล กรุณารอสักครู่..
